US2012322984A1PendingUtilityA1

Methods of reducing trail-induced apoptosis by trail isoforms

38
Individually held — no corporate assignee on recordPriority: Aug 4, 2006Filed: Aug 22, 2012Published: Dec 20, 2012
Est. expiryAug 4, 2026(~0 yrs left)· nominal 20-yr term from priority
Inventors:Andrew D. BadleyGary D. BrenDavid J. Schnepple
A61P 31/18A61P 3/10A61P 35/00A61P 43/00A61P 1/16C07K 2319/30C07K 14/70575A61K 2039/505A61P 13/08
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a mammal having an apoptosis-associated condition are provided.

Claims

exact text as granted — not AI-modified
1 . A substantially pure antibody having the ability to bind to a polypeptide having TRAIL-s activity to a level greater than the level of binding to a TRAILα, TRAILβ, or TRAILγ polypeptide. 
     
     
         2 . The antibody of  claim 1 , wherein said antibody has a dissociation constant that is less than 10 −7  for said polypeptide having TRAIL-s activity. 
     
     
         3 . The antibody of  claim 1 , wherein said polypeptide having TRAIL-s activity is a human TRAIL-s polypeptide. 
     
     
         4 . The antibody of  claim 1 , wherein said polypeptide having TRAIL-s activity is a polypeptide having the sequence set forth in SEQ ID NO:1. 
     
     
         5 . The antibody of  claim 1 , wherein said polypeptide having TRAIL-s activity is a polypeptide having the sequence set forth in SEQ ID NO:2. 
     
     
         6 . The antibody of  claim 1 , wherein said antibody has no detectable binding to a TRAILα, TRAILβ, or TRAILγ polypeptide. 
     
     
         7 . The antibody of  claim 1 , wherein said antibody has a dissociation constant that is greater than 10 −6  for binding a TRAILα, TRAILβ, or TRAILγ polypeptide. 
     
     
         8 . The antibody of  claim 1 , wherein said antibody is a monoclonal antibody. 
     
     
         9 . The antibody of  claim 1 , wherein said antibody is a human monoclonal antibody. 
     
     
         10 . The antibody of  claim 1 , wherein said antibody is a polyclonal antibody. 
     
     
         11 . The antibody of  claim 1 , wherein said antibody is a humanized monoclonal antibody. 
     
     
         12 . A substantially pure antibody that binds an epitope of the sequence set forth in SEQ ID NO:2. 
     
     
         13 . The antibody of  claim 12 , wherein said antibody is a monoclonal antibody. 
     
     
         14 . The antibody of  claim 12 , wherein said antibody is a human monoclonal antibody. 
     
     
         15 . The antibody of  claim 12 , wherein said antibody is a polyclonal antibody. 
     
     
         16 . The antibody of  claim 12 , wherein said antibody is a humanized monoclonal antibody. 
     
     
         17 . A recombinant or synthetic antibody that binds an epitope of the sequence set forth in SEQ ID NO:2. 
     
     
         18 . The antibody of  claim 17 , wherein said antibody is a monoclonal antibody. 
     
     
         19 . The antibody of  claim 17 , wherein said antibody is a human monoclonal antibody. 
     
     
         20 . The antibody of  claim 17 , wherein said antibody is a humanized monoclonal antibody.

Join the waitlist — get patent alerts

Track US2012322984A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.